The DOI matches its Crossref record.
Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or obesity in the SELECT trial
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
- Findingown data
In SELECT, among 17,604 patients with overweight/obesity and cardiovascular disease but not type 2 diabetes, weekly subcutaneous semaglutide 2.4 mg significantly reduced MACE versus placebo.
“In SELECT, among 17,604 patients with overweight/ obesity and cardiovascular (CV) disease but not type 2 diabetes (T2D), weekly subcutaneous semaglutide 2.4 mg significantly reduced major adverse cardiovascular events (MACE) versus placebo.”
- Also stated in: § Abstract · plain
“semaglutide reduced CV risk as compared with placebo (Panel A)”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
Semaglutide reduced hsCRP significantly (37.8% at 104 weeks) versus placebo.
“Semaglutide reduced hsCRP significantly (37.8%, 104 weeks) versus placebo.”
Quote in the paperSubstantial claim - Findingown data
Higher baseline hsCRP values (subgroups <2, 2-<10, 10 mg/L) were prognostic of increased MACE risk.
“Higher values in baseline hsCRP subgroups (<2, 2-<10, 10 mg/L) were prognostic of increased MACE risk”
Quote in the paperSubstantial claim - Findingown data
Semaglutide's effect on MACE was independent of LDL cholesterol levels, statin use, and CV disease entry criteria.
“Semaglutide's effects on hsCRP and MACE, which occurred early in the trial, were independent of low-density lipoprotein cholesterol levels, statin use, and CV disease entry criteria.”
Quote in the paperSubstantial claim - Findingown data
Semaglutide's effects on hsCRP and MACE occurred early in the trial.
“Semaglutide's effects on hsCRP and MACE, which occurred early in the trial, were independent of low-density lipoprotein cholesterol levels, statin use, and CV disease entry criteria.”
Quote in the paperSubstantial claim
- Findingown data
Semaglutide's effect on hsCRP was independent of LDL cholesterol levels, statin use, and CV disease entry criteria.
“Semaglutide's effects on hsCRP and MACE, which occurred early in the trial, were independent of low-density lipoprotein cholesterol levels, statin use, and CV disease entry criteria.”
Quote in the paperSubstantial claim - Findingown data
Greater weight loss was associated with larger hsCRP reductions in both semaglutide and placebo groups.
“Greater weight loss was associated with larger hsCRP reductions in the semaglutide and placebo groups (Panel B).”
- Also stated in: § Abstract · plain
“greater weight loss was associated with greater hsCRP reduction”
Quote in the paperNot a substantial claim - Also stated in: § Abstract · plain
- Interpretationown data
Among patients with overweight/obesity and CVD without T2D enrolled in SELECT, baseline hsCRP was a prognostic biomarker for MACE.
“Among patients with overweight/obesity and CVD without T2D enrolled in SELECT, baseline hsCRP was a prognostic biomarker for MACE”
Quote in the paperSubstantial claim - Study design and conductown data
Baseline hsCRP was similar between the semaglutide and placebo groups (median 1.87 mg/L vs 1.80 mg/L).
“Baseline hsCRP was similar for the semaglutide (median 1.87 mg/L) and placebo (median 1.80 mg/L) groups.”
Quote in the paperNot a substantial claim
- Borderline: one of the tests for a substantial claim is unclear. 1
Borderline substantial claim. It is unclear why the paper says it holds.
Findingnone givenSemaglutide significantly reduced MACE across all baseline hsCRP and clinical subgroups.
“Semaglutide significantly reduced MACE across all baseline hsCRP and clinical subgroups.”
Quote in the paperNot a substantial claim
The paper relies on this without support.
There is a relationship between inflammation, obesity, and atherosclerotic complications.
“Given the relationship between inflammation, obesity and atherosclerotic complications”
Citations
Cited by
Sorted by citations
Semaglutide for adults living with obesity
Bracchiglione, J., Meza, N., Franco, J. V. A., Liquitay, C. M. E., Victoria Novik, A., Vargas, M. O., Lazcano, G., Poloni, D., Langlotz, F. R., Figuls, M. R. I., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092.pub2 · Cited by 18
Oral semaglutide and reduction in major adverse cardiovascular events
Duell, P. B., & Maki, K. C. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.001 · Cited by 1
Metadata
- Authors
- Plutzky, J., Bogdański, P., Dagdelen, S., Deanfield, J., Emerson, S., Hovingh, G., Kahn, S., Larsen, S., Latkovskis, G., Lehrke, M., Hardt-Lindberg, S., Lingvay, I., Nicholls, S., Oral, T., Terns, P. P., Rasmussen, S., Ridker, P., Ryan, D., & Lincoff, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Poznan University of Medical Sciences (PL)
- University College London (GB)
- University of Washington (US)
- Novo Nordisk (Denmark) (DK)
- University of Latvia (LV)
- Universitätsklinikum Aachen (DE)
- The University of Texas Southwestern Medical Center (US)
- Monash University (AU)
- Pennington Biomedical Research Center (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 395
- Pages
- 118518
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W4401602291
- Semantic Scholar
- 1db193d9894d0740f35dc5483e441a80c1dd7bfa
- Cited by
- 2
- References
- 0
- Citations by year
- 2025: 2
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Atherosclerosis (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, inflammatory markers, cardiovascular outcomes, major adverse cardiovascular events, obesity, overweight, SELECT trial, GLP-1 receptor agonists, cardiovascular risk prediction, weight change
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
